THYROCARE Thyrocare Technologies Q2 FY26 results (Jul–Sep 2025) and concall
Thyrocare Technologies reported a strong Q2 FY26, achieving record consolidated revenue of INR 217 crores, up 22% YoY, and a significant 470 basis points expansion in standalone normalized EBITDA margin to 36%. This performance was supported by robust test volume growth (21% YoY) and strategic initiatives like franchisee expansion and operational efficiencies. The company also announced a 2:1 bonus share issue and an interim dividend, while acknowledging muted fever-related volumes and seasonal softness expected in Q3.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q2 FY26: revenue up 22.6%, net profit up 84.6% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|
| Revenue | 177 | 166 | 187 | 193 | 217 +23% |
| EBITDA | 48 | 42 | 57 | 58 | 71 +48% |
| Net profit | 26 | 19 | 22 | 38 | 48 +85% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
